PeerVoice

A 45-year-old man is diagnosed with a T3N1 tumour, identified through oesophagogastroduodenoscopy (OGD). The patient began fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy and underwent surgical resection. After 9 months, CT showed three lung metastases. At this point, the original biopsy was tested for HER2 and found to be positive (3+). He has since progressed on capecitabine and oxaliplatin (CAPOX) and trastuzumab as well as paclitaxel and ramucirumab. What would be the most appropriate next step in managing this patient? Join expert Elizabeth Smyth, MD, FRCP, in this series on patients with HER2+ gastric/gastroesophageal junction (GEJ) cancer.  #PeerVoice #meded #pathology #oncology https://lnkd.in/eTkT44WT

Many thanks to our superb faculty, Elena Castro, Fred Saad and Prof. Dr. Martin Bögemann, FEBU, for delivering an excellent CE-Accredited Satellite Symposium at #ESMO24 “Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences”. Thank you to all participants onsite and online! For those who were unable to join us live, you will soon be able to view the session at: https://lnkd.in/ejMA9fEx #PeerVoice #MedEd #MedX #CME #Oncology #prostatecancer #mHSPC #nmCRPC

A huge thank you to our wonderful faculty Peter Schmid, Cristina Saura Manich, and Aditya Bardia for delivering an insightful CE Satellite Symposium at #ESMO24 “Staying at the Forefront of HER2- and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer.” Thank you to all those who participated in the session, and to the PeerVoice team who successfully organised another excellent event! For those who were unable to join us live, you will soon be able to view the session online at: https://lnkd.in/e9dwAHSv #MedEd #MedX #CME #Oncology #breastcancer

Happening now: Our second symposium of the day “Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences” at #ESMO24 Don’t miss the replay in the coming days: https://lnkd.in/ejMA9fEx #PeerVoice #MedEd #MedX #CME #Oncology #prostatecancer #mHSPC #nmCRPC

Happening now: Full room for “Staying at the Forefront of HER2- and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer” at #ESMO24 Catch the replay in the next coming days: https://lnkd.in/e9dwAHSv #breastcancer #oncology #cme #meded

We have another great CE-Accredited Satellite Symposium coming up at #ESMO24.  Don’t miss your chance to join us tomorrow, 15 September at 18:30 in the Salamanca Auditorium, for “Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences” with Elena Castro, MD, PhD, Fred Saad, MD, and Martin Boegemann, MD. https://lnkd.in/ejMA9fEx #PeerVoice #MedEd #MedX #CME #Oncology #prostatecancer #mHSPC #nmCRPC

The PeerVoice team has arrived in Barcelona and we are ready for a busy #ESMO24! We look forward to seeing you tomorrow, 15 Sept at our CE lunch Satellite Symposium on #breastcancer at 13:00pm, Alicante Auditorium, Hall 3, Level 0 with Drs Peter Schmid, Cristina Saura Manich, and Aditya Bardia. Topic: “Staying at the Forefront of HER2- and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer,” Website: https://lnkd.in/eMbiz4dp

We are super excited to be attending #ESMO24 this weekend and to be hosting 2 satellite symposia on Sunday 15th September. Staying at the Forefront of HER2- and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer Sunday, 15 September 2024 – 13:00 – 14:30 CEST https://lnkd.in/ejB-CZdu Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences Sunday, 15 September 2024 – 18:30 – 20:00 CEST https://lnkd.in/eKKWtQ8X Please reach out to Yvonne Oliver, Caitriona Forde, Bernat Ormaetxea Gisasola, Ken Zangina and/or Toby Borger if you wish to grab a coffee with us and discuss global IME/CME.

Which treatments have shown an improved response rate in patients with advanced gastroenteropancreatic tumours (GEP-NETs)? Join expert Simon Singh, MD, MPH, in this series on advanced GEP-NETs.  #PeerVoice #meded #GEPNET #neuroendocrine #oncology https://lnkd.in/epHA6qn5

How have the 2024 KDIGO guidelines for chronic kidney disease (CKD) been updated? How do these changes impact clinical practice for both primary care and nephrology? Join the experts in this new IME activity as they walk through the most salient updates and illustrate these practice points using two case vignettes. #PeerVoice #meded #Nephrology #CKD #KDIGO #KidneyDisease https://lnkd.in/eNyc7Tdm